{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:29:17Z","timestamp":1790648957846,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006103.pub6","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T00:00:00Z","timestamp":1462752000000}}],"reference-count":373,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006103.pub7","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T11:21:40Z","timestamp":1462792900000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":191,"title":["Nicotine receptor partial agonists for smoking cessation"],"prefix":"10.1002","author":[{"given":"Kate","family":"Cahill","sequence":"first","affiliation":[{"name":"University of Oxford; Nuffield Department of Primary Care Health Sciences; Radcliffe Observatory Quarter Woodstock Road Oxford UK OX2 6GG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Lindson-Hawley","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Primary Care Health Sciences; Radcliffe Observatory Quarter Woodstock Road Oxford UK OX2 6GG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla H","family":"Thomas","sequence":"additional","affiliation":[{"name":"University of Bristol; School of Social and Community Medicine; Canynge Hall 39 Whatley Road Bristol UK BS8 2PS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R","family":"Fanshawe","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Primary Care Health Sciences; Radcliffe Observatory Quarter Woodstock Road Oxford UK OX2 6GG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Lancaster","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Primary Care Health Sciences; Radcliffe Observatory Quarter Woodstock Road Oxford UK OX2 6GG"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,5,9]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-159-6-201309170-00005","article-title":"Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial.[Summary for patients in Ann Intern Med. 2013 Sep 17;159(6):I-36; PMID: 24042380]","volume":"159","author":"Anthenelli","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0002|cit2","unstructured":"Pfizer Inc Safety and efficacy of 12 weeks of varenicline for smoking cessation in smokers with depression clinicaltrials.gov\/ct2\/ (accessed 2\/11\/2010) 2010"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub7-BIB0003|cit3","first-page":"752","article-title":"Authors' reply [to JE Rose]","volume":"63","author":"Aubin","year":"2008","journal-title":"Thorax"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub7-BIB0004|cit4","first-page":"752","article-title":"Authors' reply [to T Hillman]","volume":"63","author":"Aubin","year":"2008","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0005|cit5","first-page":"1","article-title":"Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised, open-label trial","volume":"1","author":"Aubin","year":"2008","journal-title":"Thorax"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub7-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/thx.2008.096081","article-title":"The place of varenicline in smoking cessation treatment","volume":"63","author":"Aveyard","year":"2008","journal-title":"Thorax"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub7-BIB0007|cit7","first-page":"752","article-title":"Clinically significant outcomes in smoking cessation","volume":"63","author":"Hillman","year":"2008","journal-title":"Thorax"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub7-BIB0008|cit8","first-page":"751","article-title":"Pre-cessation varenicline treatment vs post-cessation NRT: an uneven playing field","volume":"63","author":"Rose","year":"2008","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jama.2015.19284","article-title":"Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks","volume":"315","author":"Baker","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.clinthera.2011.04.013","article-title":"Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study","volume":"33","author":"Bolliger","year":"2011","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-011-2327-z","article-title":"Varenicline effects on craving, cue reactivity, and smoking reward","volume":"218","author":"Brandon","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006103.pub7-BIB0012|cit12","first-page":"16 [O027]","article-title":"Cost effectiveness of an inpatient smoking cessation intervention for patients with tobacco related illnesses (Stop Trial): a multi-centre RCT [Abstract]","volume":"18","author":"Brinn","year":"2013","journal-title":"Respirology (Carlton, Vic.)"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0013|cit13","first-page":"115","article-title":"Superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 24-month randomized controlled trial for inpatients","volume":"20","author":"Carson","year":"2015","journal-title":"Respirology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006103.pub7-BIB0014|cit14","first-page":"A30","article-title":"Varenicline tartrate and counselling versus counselling alone in a randomised controlled trial for inpatient smoking cessation: 3 month interim results [Abstract]","volume":"15","author":"Carson","year":"2010","journal-title":"Respirology"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub7-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/ntr\/ntu112","article-title":"Safety of varenicline tartrate and counseling versus counseling alone for smoking cessation: a randomized controlled trial for inpatients (STOP study)","volume":"16","author":"Carson","year":"2014","journal-title":"Nicotine & Tobacco Research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006103.pub7-BIB0016|cit16","first-page":"40 [TO 076]","article-title":"Triggers resulting in relapse: cohort analysis from the smoking termination opportunity for inpatients (STOP) trial [Abstract]","volume":"19","author":"Hnin","year":"2014","journal-title":"Respirology (Carlton, Vic.)"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/thoraxjnl-2012-202484","article-title":"Smoking termination opportunity for in patients (STOP): Superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: A 12-month randomised controlled trial for inpatients","volume":"68","author":"Smith","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Smith BJ Peters MJ Fitridge RA Esterman AJ Litt JC Horowitz JD Varenicline tartrate and counselling versus counselling alone in a randomised controlled trial for inpatient smoking cessation: 6 month interim results Not stated 2011","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A5445"},{"issue":"7","key":"10.1002\/14651858.CD006103.pub7-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4088\/JCP.13m08756","article-title":"Varenicline for smoking cessation in bipolar disorder: A randomized, double-blind, placebo-controlled study","volume":"75","author":"Chengappa","year":"2014","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0020|cit20","unstructured":"NCT01010204 Varenicline treatment for smoking cessation in patients with bipolar disorder (BEST) ClinicalTrials.gov\/ct2\/"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/eb-2013-101619","article-title":"Randomised controlled trial: Study suggests varenicline safe and effective among adults with stable depression","volume":"19","author":"Cinciripini","year":"2014","journal-title":"Evidence-based Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamapsychiatry.2013.678","article-title":"Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal","volume":"70","author":"Cinciripini","year":"2013","journal-title":"JAMA Psychiatry (Chicago, Ill.)"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/eb-2013-101435","article-title":"Varenicline may reduce negative effect while aiding smoking cessation","volume":"19","author":"Hays","year":"2014","journal-title":"Evidence-based Medicine"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0024|cit24","unstructured":"NCT00507728 Pharmacogenetics, emotional reactivity and smoking ClinicalTrials.gov\/ct2\/"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jsat.2012.01.004","article-title":"Project Impact: a pharmacotherapy pilot trial investigating the abstinence and treatment adherence of Latino light smokers","volume":"43","author":"Dios","year":"2012","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0026|cit26","unstructured":"A phase 4, randomized, double blind, active and placebo controlled multicenter study evaluating the neuropsychiatric safety and efficacy of 12 weeks varenicline tartrate 1mg BID and bupropion hydrochloride 150 mg BID for smoking cessation in subjects with and without a history of psychiatric disorders [EAGLES] clinicaltrials.gov\/ct2\/show\/NCT01456936"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0027|cit27","unstructured":"Anthenelli R Benowitz N West R St Aubin L McRae T Lawrence D Reports of suicidal ideation and behavior in the EAGLES trial Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March 2016 8"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Anthenelli RM Benowitz NL West R St Aubin L McRae T Lawrence D Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial Lancet dx.doi.org\/10.1016\/S0140-6736(16)30272-0","DOI":"10.1016\/S0140-6736(16)30272-0"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0029|cit29","unstructured":"Benowitz N Evins AE West R St Aubin L McRae T Lawrence D EAGLES trial: study design and neuropsychiatric safety results Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March 2016 7"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0031|cit30","unstructured":"Prochaska J Neuropsychiatric risk concerns in the context of smoking, quitting, and cessation pharmacotherapy use Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March 2016 7"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0030|cit31","unstructured":"Prochaska J Benowitz N West R Anthenelli R Evaluating adverse events in a global smoking cessation study (EAGLES): a randomized controlled tiral comparing the safety and efficacy of the first-line smoking cessation aids in smokers with and without pychiatric disorders Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March 2016 7"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0032|cit32","unstructured":"West R Benowitz N Evins AE St Aubin L McRae T Lawrence D Relative efficacy of varenicline, bupropion SR, and nicotine transdermal patch in aiding smoking cessation in the EAGLES trial Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March 2016 8"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub7-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/ntr\/ntr078","article-title":"A pilot study to assess smokeless tobacco use reduction with varenicline","volume":"13","author":"Ebbert","year":"2011","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0034|cit34","unstructured":"Bastian H Comment on Ebbert 2015 'Reduce to Quit' trial www.ncbi.nlm.nih.gov\/pubmed\/?term=25688780"},{"issue":"7","key":"10.1002\/14651858.CD006103.pub7-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.280","article-title":"Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial","volume":"313","author":"Ebbert","year":"2015","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0036|cit36","unstructured":"NCT01370356 A study to evaluate the efficacy and safety of varenicline compared to placebo for smoking cessation through reduction clinicaltrials.gov\/ct2\/"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.115.019634","article-title":"Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome","volume":"133","author":"Eisenberg","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2015.07.010","article-title":"A randomized controlled trial of the efficacy and safety of varenicline for smoking cessation after acute coronary syndrome: Design and methods of the Evaluation of Varenicline in Smoking Cessation for Patients Post-Acute Coronary Syndrome trial","volume":"170","author":"Windle","year":"2015","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0040|cit39","first-page":"S63","article-title":"Extended duration pharmacotherapy with varenicline prevents relapse to smoking in adult smokers with schizophrenia","volume":"38","author":"Evins","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0039|cit40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.2013.285113","article-title":"Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: A randomized clinical trial","volume":"311","author":"Evins","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0041|cit41","unstructured":"NCT00621777 A study of varenicline for prevention of relapse to smoking in patients with schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00621777"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/15504263.2012.663675","article-title":"Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week open-label trial","volume":"8","author":"Pachas","year":"2012","journal-title":"Jounrla of Dual Diagnosis"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clinthera.2009.01.003","article-title":"Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"31","author":"Faessel","year":"2009","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"c6549","DOI":"10.1136\/bmjc6549","article-title":"Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial","volume":"341","author":"Fagerstr\u00f6m","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.biopsych.2010.12.005","article-title":"A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo","volume":"69","author":"Garza","year":"2011","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0046|cit46","unstructured":"Gonzales D Jorenby DE Brandon T Arteaga C Lee TC Delayed quitting, lapse recovery and long-term outcomes for quitters taking varenicline, bupropion and placebo Society for Research on Nicotine and Tobacco Annual Meeting, Portland OR, Feb 27-March 1st 2008"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0047|cit47","unstructured":"Gonzales D Jorenby DE Brandon TH Arteaga C Lee TC Emergent adverse psychiatric symptoms by therapy during 12 weeks of treatment with varenicline, bupropion SR, or placebo for smoking cessation Society for Research on Nicotine and Tobacco Europe: Rome, September 23-26 2008"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub7-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/j.1360-0443.2010.03058.x","article-title":"Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo","volume":"105","author":"Gonzales","year":"2010","journal-title":"Addiction"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.296.1.47","article-title":"Varenicline, an \u03b14\u00df2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation","volume":"296","author":"Gonzales","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ntr\/ntq047","article-title":"Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence","volume":"12","author":"Hays","year":"2010","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.drugalcdep.2009.12.022","article-title":"Predictors of post-treatment relapse to smoking in successful quitters: pooled data from two phase III varenicline trials","volume":"109","author":"Heffner","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/JOM.0b013e3180459ff2","article-title":"An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation","volume":"49","author":"Jackson","year":"2007","journal-title":"Journal of Occupational and Environmental Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"664","DOI":"10.5993\/AJHB.32.6.10","article-title":"Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis","volume":"32","author":"Nides","year":"2008","journal-title":"American Journal of Health Behavior"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11920-007-0044-4","article-title":"A new medication for the worst addiction","volume":"9","author":"O'Brien","year":"2007","journal-title":"Current Psychiatry Reports"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/clpt.2009.282","article-title":"Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation","volume":"87","author":"Ravva","year":"2010","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0056|cit56","first-page":"167","article-title":"Practical implementation of varenicline as an aid to smoking cessation in clinical practice","volume":"58","author":"Tonstad","year":"2009","journal-title":"Pneumologia"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"West R Baker CL Cappelleri JC Bushmakin AG Effect of varenicline and bupropion on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt UK National Smoking Cessation Conference Proceedings, London, June 2007 2007","DOI":"10.1007\/s00213-007-1041-3"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2165\/11589230-000000000-00000","article-title":"A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data","volume":"29","author":"Xenakis","year":"2011","journal-title":"PharmacoEconomics"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/clpt.2014.124","article-title":"Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: A randomized, placebo-controlled trial","volume":"96","author":"Gonzales","year":"2014","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0060|cit60","unstructured":"NCT01244061 A multi-national study to assess how effective and safe the smoking cessation medicine varenicline is in smokers who have already tried varenicline in the past as a prescription medicine from their usual healthcare provider ClinicalTrials.gov\/ct2\/"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jamainternmed.2014.6916","article-title":"Increasing varenicline dose in smokers who do not respond to the standard dosage: a randomized clinical trial","volume":"175","author":"Hajek","year":"2015","journal-title":"JAMA Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"268","DOI":"10.5588\/ijtld.11.0183","article-title":"Quitting smoking with varenicline: parallel, randomised efficacy trial in Iran","volume":"16","author":"Heydari","year":"2012","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub7-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/ntr\/ntr103","article-title":"Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial","volume":"13","author":"Hughes","year":"2011","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0064|cit64","unstructured":"NCT00595868 Efficacy of varenicline in ambivalent smokers ClinicalTrials.gov\/ct2\/show\/NCT00595868"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Efficacy of varenicline, an \u03b14\u00df2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation","volume":"296","author":"Jorenby","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0066|cit66","first-page":"348","article-title":"A second varenicline trial","volume":"9","author":"O'Brien","year":"2007","journal-title":"Current Psychiatry Reports"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ntr\/nts101","article-title":"Effects of varenicline on abstinence and smoking reward following a programmed lapse","volume":"15","author":"McClure","year":"2013","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0068|cit68","unstructured":"NCT00944554 Varenicline for relapse prevention ClinicalTrials.gov\/ct2\/"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/JCP.0b013e3182870551","article-title":"Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial","volume":"33","author":"Meszaros","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0070|cit70","first-page":"393","article-title":"Varenicline treatment of alcohol and nicotine dependence in schizophrenia: Problems encountered in a pilot trial","volume":"21","author":"Meszaros","year":"2012","journal-title":"American Journal on Addictions \/ American Academy of Psychiatrists in Alcoholism and Addictions"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0071|cit71","unstructured":"NCT00727103 Varenicline treatment in alcohol and nicotine dependent patients with schizophrenia ClinicalTrials.gov\/ct2\/"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00213-012-2717-x","article-title":"Varenicline decreases alcohol consumption in heavy-drinking smokers","volume":"223","author":"Mitchell","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0073|cit73","unstructured":"NCT01027754 Smoking cessation treatment for methadone maintenance patients ClinicalTrials.gov\/ct2\/"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub7-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/add.12631","article-title":"Varenicline efficacy and safety among methadone maintained smokers: A randomized placebo-controlled trial","volume":"109","author":"Nahvi","year":"2014","journal-title":"Addiction (Abingdon, England)"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub7-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1185\/03007995.2010.505130","article-title":"Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries","volume":"26","author":"Fagerstr\u00f6m","year":"2010","journal-title":"Current medical Research & Opinion"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/00019053-200927030-00007","article-title":"Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan","volume":"27","author":"Igarashi","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.clinthera.2007.06.012","article-title":"Efficacy and tolerability of nicotinic varenicline, an alpha4beta2 acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers","volume":"29","author":"Nakamura","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.clinthera.2007.06.012","article-title":"Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers","volume":"29","author":"Nakamura","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.clinthera.2014.03.013","article-title":"Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in japanese smokers","volume":"36","author":"Nakamura","year":"2014","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0080|cit80","unstructured":"NCT00828113 Varenicline for long-term smoking cessation ClinicalTrials.gov\/ct2\/"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0081|cit81","unstructured":"NCT01347112 Varenicline treatment for active alcoholic smokers ClinicalTrials.gov\/ct2\/"},{"issue":"7","key":"10.1002\/14651858.CD006103.pub7-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1185\/03007990802177523","article-title":"The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial","volume":"24","author":"Niaura","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"664","DOI":"10.5993\/AJHB.32.6.10","article-title":"Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis","volume":"32","author":"Nides","year":"2008","journal-title":"American Journal of Health Behavior"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.166.15.1561","article-title":"Smoking cessation with varenicline, a selective \u03b14\u03b22 nicotinic receptor partial agonist","volume":"166","author":"Nides","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0085|cit85","unstructured":"Oncken C Watsky E Reeves K Anziano R Varenicline is efficacious and well tolerated in promoting smoking cessation: Results from a 7-week, randomized, placebo- and bupropion-controlled trial [POS1-047] Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic 2005"},{"issue":"15","key":"10.1002\/14651858.CD006103.pub7-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/archinte.166.15.1571","article-title":"Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation","volume":"166","author":"Oncken","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0087|cit87","unstructured":"Oncken C Watsky E Reeves K Anziano R Smoking cessation with varenicline, a selective nicotinic receptor partial agonist: results from a phase 2 study [POS1-046] Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic 2005"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jsat.2013.08.015","article-title":"Association of deferring a quit attempt with smoking cessation success: a secondary analysis","volume":"46","author":"Hughes","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"12","key":"10.1002\/14651858.CD006103.pub7-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.addbeh.2011.08.001","article-title":"Efficacy of a flexible quit date versus an a priori quit date approach to smoking cessation: a cross-study analysis","volume":"36","author":"Hughes","year":"2011","journal-title":"Addictive Behaviors"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ntr\/ntr220","article-title":"A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates","volume":"14","author":"Rennard","year":"2012","journal-title":"Nicotine & Tobacco Research"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/CIRCULATIONAHA.109.915546","article-title":"Varenicline for smoking cessation in patients with coronary heart disease [editorial]","volume":"121","author":"Ockene","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0092|cit92","first-page":"2","article-title":"A randomized trial of varenicline for smoking cessation in patients with cardiovascular disease: analysis of efficacy by baseline characteristics","volume":"Conference","author":"Rigotti","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/CIRCULATIONAHA.109.869008","article-title":"Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease","volume":"121","author":"Rigotti","year":"2010","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub7-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1161\/CIRCULATIONAHA.110.960856","article-title":"Response to letter regarding article, efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial","volume":"122","author":"Rigotti","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0095|cit95","unstructured":"NCT00894166 Evaluation of a tailored smoking cessation treatment algorithm based on initial treatment response and genotype (ConNIC3) ClinicalTrials.gov\/ct2\/"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub7-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1176\/appi.ajp.2013.12070919","article-title":"Adapting smoking cessation treatment according to initial response to precessation nicotine patch","volume":"170","author":"Rose","year":"2013","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/mp.2012.155","article-title":"Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances","volume":"19","author":"Uhl","year":"2014","journal-title":"Molecular Psychiatry"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0098|cit98","first-page":"774","article-title":"Smoking cessation treatment with cytisin (Tabex\u00ae): half-yearly outcomes for former smokers abstinent at four weeks from beginning of treatment","volume":"24","author":"Benndorf","year":"1970","journal-title":"Das Deutsche Gesundheitwesen"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0099|cit99","first-page":"1135","article-title":"Further reports on a double blind trial of the Bulgarian cytisine compound Tabex\u00ae on 1214 smokers wishing to quit and practical experience in conducting clinics for such smokers","volume":"24","author":"Benndorf","year":"1969","journal-title":"Das Deutsche Gesundheitswesen"},{"issue":"44","key":"10.1002\/14651858.CD006103.pub7-BIB0100|cit100","first-page":"2092","article-title":"Results of smoking cessation treatment with cytisin (Tabex\u00ae)","volume":"23","author":"Benndorf","year":"1968","journal-title":"Das Deutsche Gesundheitwesen"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub7-BIB0101|cit101","first-page":"463","article-title":"Cytisine (Tabex\u00ae) as a treatment for smoking cessation","volume":"26","author":"Scharfenberg","year":"1971","journal-title":"Das Deutsche Gesundheitwesen"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub7-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/ntr\/ntu099","article-title":"Early quit days among methadone-maintained smokers in a smoking cessation trial","volume":"16","author":"Dios","year":"2014","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0103|cit103","unstructured":"NCT00790569 Varenicline versus nicotine replacement for methadone-maintained smokers ClinicalTrials.gov\/ct2\/"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.drugalcdep.2013.07.005","article-title":"Varenicline for smoking cessation among methadone-maintained smokers: A randomized clinical trial","volume":"133","author":"Stein","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"12","key":"10.1002\/14651858.CD006103.pub7-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.addbeh.2011.07.002","article-title":"Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline","volume":"36","author":"Steinberg","year":"2011","journal-title":"Addictive Behaviors"},{"issue":"16","key":"10.1002\/14651858.CD006103.pub7-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1517\/14656566.2011.605786","article-title":"Varenicline for smoking cessation intervention in chronic obstructive pulmonary disease","volume":"12","author":"Antoniu","year":"2011","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1378\/chest.10-2919","article-title":"What justifies a placebo-controlled trial of varenicline for smoking cessation in patients with COPD? [comment]","volume":"139","author":"Kotz","year":"2011","journal-title":"Chest"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1378\/chest.10-0865","article-title":"Effects of varenicline on smoking cessation in mild-to-moderate COPD: a randomized controlled trial","volume":"139","author":"Tashkin","year":"2011","journal-title":"Chest"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub7-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.rmed.2011.04.016","article-title":"Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients","volume":"105","author":"Tashkin","year":"2011","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1365-2753.2008.01045.x","article-title":"Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence","volume":"15","author":"Bolin","year":"2009","journal-title":"Journal of Evaluation in Clinical Practice"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1360-0443.2009.02646.x","article-title":"Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment","volume":"104","author":"Hajek","year":"2009","journal-title":"Addiction"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1524-4733.2009.00672.x","article-title":"The cost-effectiveness of an extended course (12 + 12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model","volume":"13","author":"Knight","year":"2010","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0113|cit113","doi-asserted-by":"crossref","unstructured":"Knight CJ Howard PA Baker CL An evaluation of the cost-effectiveness of an extended course of varenicline in preventing smokers who have quit from relapsing [PSM3] Value in Health 2007 A472","DOI":"10.1016\/S1098-3015(10)65622-7"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1751-7141.2008.00003.x","article-title":"A longer course of varenicline therapy improves smoking cessation rates","volume":"11","author":"Lee","year":"2008","journal-title":"Preventive Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0115|cit115","first-page":"348","article-title":"Varenicline as maintenance therapy","volume":"9","author":"O'Brien","year":"2007","journal-title":"Current Psychiatry Reports"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.296.1.64","article-title":"Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial","volume":"296","author":"Tonstad","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ntr\/ntq191","article-title":"Dianicline, a novel \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial","volume":"13","author":"Tonstad","year":"2011","journal-title":"Nicotine & Tobacco Research"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub7-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1185\/03007995.2010.505130","article-title":"Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries","volume":"26","author":"Fagerstr\u00f6m","year":"2010","journal-title":"Current medical Research & Opinion"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.clinthera.2007.06.011","article-title":"A randomized, placebo-controlled trial of varenicline, a selective \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers","volume":"29","author":"Tsai","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1253\/circj.CJ-10-0165","article-title":"Smoking is a disease and smokers are patients","volume":"74","author":"Fujiwara","year":"2010","journal-title":"Circulation Journal"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1253\/circj.CJ-09-0803","article-title":"A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers","volume":"74","author":"Tsukahara","year":"2010","journal-title":"Circulation Journal"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0122|cit122","unstructured":"NCT00977249 Varenicline for long-term NRT users ClinicalTrials.gov\/ct2\/"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/ntr\/nts146","article-title":"Varenicline to stop long-term nicotine replacement use: a double-blind, randomized, placebo-controlled trial","volume":"15","author":"T\u00f8nnesen","year":"2013","journal-title":"Nicotine & Tobacco Research"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1375\/jsc.3.1.57","article-title":"A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers","volume":"3","author":"Vinnikov","year":"2008","journal-title":"Journal of Smoking Cessation"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1186\/1471-2458-11-880","article-title":"Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking","volume":"11","author":"Walker","year":"2011","journal-title":"BMC Public Health"},{"issue":"25","key":"10.1002\/14651858.CD006103.pub7-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1056\/NEJMoa1407764","article-title":"Cytisine versus nicotine for smoking cessation","volume":"371","author":"Walker","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub7-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1056\/NEJMc1500342","article-title":"Cytisine versus nicotine for smoking cessation","volume":"372","author":"Zatonski","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub7-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1185\/03007995.2010.505130","article-title":"Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries","volume":"26","author":"Fagerstr\u00f6m","year":"2010","journal-title":"Current medical Research & Opinion"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1440-1843.2008.01476.x","article-title":"Varenicline for smoking cessation: a placebo-controlled, randomized study","volume":"14","author":"Wang","year":"2009","journal-title":"Respirology"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0131|cit130","doi-asserted-by":"crossref","first-page":"JC1","DOI":"10.7326\/0003-4819-156-2-201201170-02006","article-title":"Cytisine increased smoking cessation in adults","volume":"156","author":"West","year":"2012","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0130|cit131","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1102035","article-title":"Placebo-controlled trial of cytisine for smoking cessation","volume":"365","author":"West","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/cea.12243","article-title":"The effect of smoking cessation on airway inflammation in young asthma patients","volume":"44","author":"Westergaard","year":"2013","journal-title":"Clinical & Experimental Allergy"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0133|cit133","first-page":"A1091","article-title":"The effect of varenicline on smoking cessation in a group of young asthma patients","volume":"189","author":"Westergaard","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub7-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.rmed.2015.07.017","article-title":"The effect of varenicline on smoking cessation in a group of young asthma patients","volume":"109","author":"Westergaard","year":"2015","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0135|cit135","unstructured":"Reeves K Watsky E Williams K Azoulay S Billing B Gong J The safety of varenicline taken for 52 weeks for smoking cessation [RPOS3-54] Society for Research on Nicotine and Tobacco 12th Annual Conference Orlando Fla, USA 2006"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1185\/030079908X261140","article-title":"Comment and reply: A double-blind study evaluating the long-term safety of varenicline for smoking cessation","volume":"24","author":"Spangler","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1185\/030079907X182185","article-title":"A double-blind study evaluating the long-term safety of varenicline for smoking cessation","volume":"23","author":"Williams","year":"2007","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0138|cit138","unstructured":"NCT00644969 Smoking cessation study for patients with schizophrenia or schizoaffective disorder ClinicalTrials.gov"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4088\/JCP.11m07522","article-title":"A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder","volume":"73","author":"Williams","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0140|cit140","unstructured":"NCT00937508 Smoking cessation program in the pre-admission clinic ClinicalTrials.gov\/ct2\/"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/ALN.0b013e3182698b42","article-title":"A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial","volume":"117","author":"Wong","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1177\/0091270006291837","article-title":"Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers","volume":"46","author":"Burstein","year":"2006","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0143|cit143","unstructured":"Pfizer Inc Chantix prescribing information http:\/\/www.chantix.com\/content\/Prescribing_Information.jsp (accessed 10th February 2007) 2006"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1089\/apc.2011.0199","article-title":"Safety and tolerability of varenicline tartrate (Champix\u00ae\/Chantix\u00ae) for smoking cessation in HIV-infected subjects: a pilot open-label study","volume":"26","author":"Cui","year":"2012","journal-title":"AIDS patient Care and STDs"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0145|cit145","first-page":"356","article-title":"Use of the Patient Health Questionnaire-2 to predict suicidal ideations in patients taking varenicline","volume":"21","author":"Cowan","year":"2012","journal-title":"American Journal on Addictions \/ American Academy of Psychiatrists in Alcoholism and Addictions"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"401","DOI":"10.7205\/MILMED-D-12-00272","article-title":"Internet versus in-person counseling for patients taking varenicline for smoking cessation","volume":"178","author":"Dezee","year":"2013","journal-title":"Military Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00213-011-2373-6","article-title":"Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity","volume":"219","author":"Dutra","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ntr\/ntn031","article-title":"Varenicline and bupropion sustained-release combination therapy for smoking cessation","volume":"11","author":"Ebbert","year":"2009","journal-title":"Nicotine & Tobacco Research"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/ntr\/ntp042","article-title":"Combination treatment with varenicline and nicotine replacement therapy","volume":"11","author":"Ebbert","year":"2009","journal-title":"Nicotine & Tobacco Research"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jama.2013.283185","article-title":"Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: A Randomized Trial","volume":"311","author":"Ebbert","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0151|cit151","unstructured":"NCT00935818 Varenicline and bupropion for smoking cessation (CHANBAN) ClinicalTrials.gov\/ct2\/"},{"issue":"Supplement s1","key":"10.1002\/14651858.CD006103.pub7-BIB0152|cit152","first-page":"139A","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence","volume":"38","author":"Falk","year":"2014","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","volume":"7","author":"Litten","year":"2013","journal-title":"Journal of Addiction Medicine"},{"issue":"1-3","key":"10.1002\/14651858.CD006103.pub7-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.schres.2013.02.015","article-title":"Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study","volume":"146","author":"Fatemi","year":"2013","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0155|cit155","unstructured":"NCT01111149 Varenicline and smoking cessation in schizophrenia (VSCS) ClinicalTrials.gov\/ct2\/"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2011.10.011","article-title":"A pilot test of a combined tobacco dependence treatment and lung cancer screening program","volume":"76","author":"Ferketich","year":"2012","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ntr\/nts121","article-title":"Safety of varenicline among smokers enrolled in the lung HIV study","volume":"15","author":"Ferketich","year":"2013","journal-title":"Nicotine & Tobacco Research"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/JCP.0b013e31829cc3cd","article-title":"A feasibility study of varenicline for smoking cessation in bipolar patients with subsyndromal depression","volume":"33","author":"Frye","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00213-010-2160-9","article-title":"A preliminary investigation of varenicline for heavy drinking smokers","volume":"215","author":"Fucito","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0160|cit160","first-page":"8","article-title":"Smoking cessation through the use of cytisine and other therapy","volume":"1","author":"Granatowicz","year":"1976","journal-title":"World Smoking Health"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ntr\/ntr130","article-title":"Varenicline versus bupropion XL for smoking cessation in older adolescents: A randomized, double-blind pilot trial","volume":"14","author":"Gray","year":"2012","journal-title":"Nicotine & Tobacco Research"},{"issue":"19","key":"10.1002\/14651858.CD006103.pub7-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1001\/archinternmed.2011.493","article-title":"Is varenicline effectiveness declining in randomized trials?","volume":"171","author":"Dhelaria","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD006103.pub7-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archinternmed.2011.494","article-title":"Is varenicline effectiveness declining in randomized trials? - Reply","volume":"171","author":"Hajek","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub7-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1001\/archinternmed.2011.138","article-title":"Use of varenicline for 4 weeks before quitting smoking","volume":"171","author":"Hajek","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub7-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/archinternmed.2011.137","article-title":"Smoking cessation interventions: a primer for physicians","volume":"171","author":"Simon","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1741-7015-11-140","article-title":"Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial","volume":"11","author":"Hajek","year":"2013","journal-title":"BMC Medicine"},{"issue":"Supplement s1","key":"10.1002\/14651858.CD006103.pub7-BIB0167|cit167","first-page":"223A","article-title":"Pharmacogenetics of naltrexone and varenicline in heavy drinking smokers","volume":"38","author":"Hartwell","year":"2014","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pbb.2015.04.013","article-title":"Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers","volume":"134","author":"Roche","year":"2015","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/clpt.2011.317","article-title":"The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial","volume":"91","author":"Hawk","year":"2012","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0170|cit170","unstructured":"NCT00835900 An alternative dosing schedule for varenicline for smoking cessation ClinicalTrials.gov\/ct2\/"},{"issue":"12","key":"10.1002\/14651858.CD006103.pub7-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2011.83","article-title":"Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder","volume":"68","author":"Hong","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0172|cit172","unstructured":"NCT00492349 Varenicline adjunctive treatment in schizophrenia ClinicalTrials.gov\/ct2\/"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub7-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/add.12573","article-title":"Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial","volume":"109","author":"Hoogsteder","year":"2014","journal-title":"Addiction (Abingdon, England)"},{"issue":"14","key":"10.1002\/14651858.CD006103.pub7-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1007\/s00213-014-3482-9","article-title":"Varenicline versus transdermal nicotine patch: a 3-year follow-up in a smoking cessation clinic in Taiwan","volume":"231","author":"Hsueh","year":"2014","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ntr\/ntt115","article-title":"A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India","volume":"16","author":"Jain","year":"2014","journal-title":"Nicotine & Tobacco Research"},{"issue":"21","key":"10.1002\/14651858.CD006103.pub7-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/eurheartj\/ehu051","article-title":"Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial","volume":"35","author":"Jennings","year":"2014","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD006103.pub7-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.mayocp.2013.08.015","article-title":"Increasing the dose of varenicline in patients who do not respond to the standard dose","volume":"88","author":"Jim\u00e9nez-Ruiz","year":"2013","journal-title":"Mayo Clinic Proceedings"},{"issue":"50","key":"10.1002\/14651858.CD006103.pub7-BIB0178|cit178","first-page":"2663","article-title":"Smoking cessation through medication: remarks on G. Scharfenberg, E Winkelvoss and S. Benndorf, Munch Med Wschr. 109 (1967) 1687-1689","volume":"109","author":"Bacvarov","year":"1967","journal-title":"Munchener Medizinische Wochenschrift"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0179|cit179","first-page":"355","article-title":"Observation about the Bulgarian medicine for smoking withdrawal Tabex, produced by Pharmachim-Sofia","volume":"18","author":"Kempe","year":"1967","journal-title":"Savr Med"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0180|cit180","first-page":"26","article-title":"Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: A randomized clinical trial. [German]","volume":"11","author":"Koegelenberg","year":"2014","journal-title":"Zeitschrift fur Gefassmedizin"},{"issue":"24","key":"10.1002\/14651858.CD006103.pub7-BIB0181|cit181","first-page":"2207","article-title":"Therapeutic use of Tabex","volume":"25","author":"Maliszewski","year":"1972","journal-title":"Wiadomoscie Lekarskie"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0182|cit182","first-page":"55","article-title":"Treatment of nicotinism [in Russian]","volume":"1","author":"Marakulin","year":"1984","journal-title":"Voenno-Meditsinskii Zhurnal"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.clpt.6100510","article-title":"Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers","volume":"83","author":"McColl","year":"2008","journal-title":"Clinical Therapeutics and Pharmacology"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1186\/1471-2458-13-824","article-title":"Extended interactive voice response telephony (IVR) for relapse prevention after smoking cessation using varenicline and IVR: a pilot study","volume":"13","author":"McNaughton","year":"2013","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0185|cit185","first-page":"109","article-title":"Pharmacological agents in controlling smoking","volume":"10","author":"Metelitsa","year":"1987","journal-title":"Biulleten Vsesoiuznogo Kardiologicheskogo Nuachnogo Tsentra AMN SSSR"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/npp.2012.205","article-title":"Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: a randomized, double-blind, study","volume":"38","author":"Mocking","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0187|cit187","unstructured":"Monova A Monova D Petrov V. Peneva E Todorova M Petrova M Final report on double blind, placebo controlled, randomized clinical study for evaluation of efficacy, safety and tolerability of Tabex in patients with chronic nicotinism (tabacism): TAB - SPH - 04014 Sopharma plc unpublished report 2004"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0188|cit188","unstructured":"NCT00502216 Naltrexone and varenicline: weight gain and tolerability in smokers ClinicalTrials.gov\/show\/NCT00502216"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0189|cit189","unstructured":"NCTNCT00502216 Naltrexone and varenicline: weight gain and tolerability on cigarette smokers ClinicalTrials.gov\/ct2\/show\/NCTNCT00502216"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0190|cit190","unstructured":"NCT01308736 Varenicline-aided cigarette reduction in smokers not ready to quit ClinicalTrials.gov\/show\/NCT01308736 2011"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0191|cit191","unstructured":"NCT01806779 Combination bupropion\/varenicline for smoking cessation in male smokers ClinicalTrials.gov\/show\/NCT01806779"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0192|cit192","doi-asserted-by":"crossref","unstructured":"Buchanan TS Berg CJ Cox LS Nazir N Benowitz NL Yu L Adherence to varenicline among African American smokers: an exploratory analysis comparing plasma concentration, pill count, and self-report Nicotine & Tobacco Research 2012 1083 91","DOI":"10.1093\/ntr\/ntr333"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub7-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/ntr\/ntr063","article-title":"A pilot clinical trial of varenicline for smoking cessation in Black smokers","volume":"13","author":"Nollen","year":"2011","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0194|cit194","first-page":"42","article-title":"Results of clinical investigation of anti-nicotine drug patches","volume":"3","author":"Ostrovskaia","year":"1994","journal-title":"Meditsinskaia Tekhnika"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/JTO.0b013e318215a4dc","article-title":"A smoking cessation intervention for thoracic surgery and oncology clinics","volume":"6","author":"Park","year":"2011","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0196|cit196","unstructured":"Lerman C Effects of Chantix on relapse prevention for smoking cessation ClinicalTrials.gov\/ct2\/"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.drugalcdep.2009.07.020","article-title":"Working memory deficits predict short-term smoking resumption following brief abstinence","volume":"106","author":"Patterson","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.biopsych.2008.08.028","article-title":"Varenicline improves mood and cognition during smoking abstinence","volume":"65","author":"Patterson","year":"2009","journal-title":"Biological Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/ntr\/ntq049","article-title":"Mouse model predicts effects of smoking and varenicline on event-related potentials in humans","volume":"12","author":"Rudnick","year":"2010","journal-title":"Nicotine & Tobacco Research"},{"issue":"44","key":"10.1002\/14651858.CD006103.pub7-BIB0200|cit200","first-page":"2088","article-title":"[Smoking cessation with cytisine 'Tabex' tablets] [German]","volume":"23","author":"Paun","year":"1968","journal-title":"Sonderduck aus das deutsche Gesundheitwesen"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0201|cit201","first-page":"15","article-title":"Tabex: registering and treatment of smokers with chronic bronchitis in the consultation against tobacco smoking - Berlin","volume":"3","author":"Paun","year":"1970","journal-title":"Medico-Biologic Information"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0202|cit202","unstructured":"Pfizer Inc Flexible Dosing Trial NDA 21-928 [reported in CDER 2006] 2006"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1521-0391.2010.00066.x","article-title":"The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study","volume":"19","author":"Poling","year":"2010","journal-title":"The American Journal on Addictions"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12916-014-0172-8","article-title":"Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation","volume":"12","author":"Ramon","year":"2014","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0205|cit205","unstructured":"NCT01303861 Concurrent bupropion\/varenicline for smoking cessation (ConNic4) ClinicalTrials.gov\/ct2\/"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub7-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1176\/appi.ajp.2014.13050595","article-title":"Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm","volume":"171","author":"Rose","year":"2014","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0207|cit207","unstructured":"Rose JE Behm FM Combination varenicline\/bupropion treatment benefits male NRT-Nonresponders Society for Research on Nicotine and Tobacco 19th Annual Meeting March 13-16 Boston MA 2013 261"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub7-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.addbeh.2014.05.008","article-title":"The impact of pre-cessation varenicline on behavioral economic indices of smoking reinforcement","volume":"39","author":"Schlienz","year":"2014","journal-title":"Addictive Behaviors"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub7-BIB0209|cit209","first-page":"557","article-title":"[Medical support of nicotine withdrawal. Report on a double blind trial in over 5000 smokers (author's transl)] [German]","volume":"116","author":"Schmidt","year":"1974","journal-title":"Munch Med Wachr"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub7-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/10410236.2011.566829","article-title":"A novel recruitment message to increase enrollment into a smoking cessation treatment program: preliminary results from a randomized trial","volume":"26","author":"Schnoll","year":"2011","journal-title":"Health Communication"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0211|cit211","first-page":"320","article-title":"Varenicline treatment for smoking cessation in people with schizophrenia: a randomized double-blind placebo-controlled trial","volume":"37","author":"Shim","year":"2011","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/npp.2011.238","article-title":"Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial","volume":"37","author":"Shim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0213|cit213","doi-asserted-by":"crossref","unstructured":"Sicras-Mainar A Navarro-Artieda R Diaz-Cerezo S Sanz de Burgoa V Effectiveness of varenicline compared with bupropion and nicotine replacement therapy (NRT) for smoking cessation in two smoking specialized units in the primary care setting Society for Research on Nicotine and Tobacco Europe Conference: Bath, UK, 6-9 October 2010","DOI":"10.1016\/S1098-3015(11)72236-7"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1360-0443.2007.02083.x","article-title":"Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness","volume":"103","author":"Stapleton","year":"2008","journal-title":"Addiction"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0215|cit215","first-page":"30","article-title":"[On the therapeutic effectiveness and tolerability of Tabex] [Bulgarian]","volume":"23","author":"Stoyanov","year":"1972","journal-title":"Savremenna Medicina"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/ntr\/ntr003","article-title":"Adherence to varenicline in the COMPASS smoking cessation intervention trial","volume":"13","author":"Catz","year":"2011","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jsat.2008.09.001","article-title":"Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting","volume":"36","author":"Halperin","year":"2009","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jsat.2010.03.007","article-title":"Smoking outcome by psychiatric history after behavioral and varenicline treatment","volume":"38","author":"McClure","year":"2010","journal-title":"Journal of Substance Abuse and Treatment"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11606-009-0926-8","article-title":"Mood, side-effects and smoking outcomes among persons with and without probably lifetime depression taking varenicline","volume":"24","author":"McClure","year":"2009","journal-title":"Journal of General Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.amepre.2010.01.024","article-title":"Behavioral counseling and varenicline treatment for smoking cessation","volume":"38","author":"Swan","year":"2010","journal-title":"American Journal of Preventive Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/ntr\/ntq257","article-title":"Utilization of services in a randomized trial testing phone- and web-based interventions for smoking cessation","volume":"13","author":"Zbikowski","year":"2011","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2011.02.003","article-title":"Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study","volume":"129","author":"Weiner","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0223|cit223","unstructured":"Zatonski W Cedzynska M Przewozniak K Karpinska E Lewandowska D Pstrucha E An open label observational study of herbal cytisine (Tabex) as an aid to smoking cessation [POS1-058] Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic 2005"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/tc.2006.016097","article-title":"An uncontrolled trial of cytisine (Tabex) for smoking cessation","volume":"15","author":"Zatonski","year":"2006","journal-title":"Tobacco Control"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006103.pub7-BIB0225|cit225","first-page":"66 [OS205]","article-title":"Efficacy of varenicline, an nicotinic acetylcholine receptor partial agonist, vs placebo for smoking cessation. A randomized controlled trial","volume":"18","author":"Wiratmoko","year":"2013","journal-title":"Respirology (Carlton, Vic.)"},{"issue":"16 SUPPL. 1","key":"10.1002\/14651858.CD006103.pub7-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"C207","DOI":"10.1016\/j.jacc.2014.06.961","article-title":"Efficacy and safety of varenicline for smoking cessation in patients with CAD undergoing PCI","volume":"64","author":"Yujie","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5455\/bcp.20130313045037","article-title":"Comparison of the effectiveness of varenicline, extended-release bupropion and nicotine replacement therapy on the success and the maintenance of a smoking cessation program","volume":"23","author":"Zincir","year":"2013","journal-title":"Bulletin of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0228|cit228","unstructured":"Nosa V Glover M TALANOA Samoa: A randomised controlled trial to evaluate the efficacy of a cessation support programme for smokers delivered via radio www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=364690"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0229|cit229","unstructured":"ACTRN12614000329662 Examination of mechanism of action of pre-quit use of nicotine patch and varenicline for smoking cessation www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=365947"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1186\/s12889-015-2596-2","article-title":"Examination of the mechanism of action of two pre-quit pharmacotherapies for smoking cessation","volume":"15","author":"Ferguson","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0231|cit231","unstructured":"ACTRN12614000876695 Improving radiotherapy outcomes with smoking cessation: Feasibility trial in head and neck cancer patients www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12614000876695"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0232|cit232","unstructured":"NCT00387946 Efficacy and safety of dianicline treatment as an aid to smoking cessation in cigarette smokers (AMERIDIAN) ClinicalTrials.gov NCT00387946"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0233|cit233","unstructured":"EUCTR2009-017599-26-IT Efficacy and safety of smoking cessation with varenicline tartrate in diabetic smokers: a double-blind, placebo-controlled, randomized trial www.clinicaltrialsregister.eu\/ctr-search\/search?query=2009-017599-26"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0234|cit234","unstructured":"ISRCTN25441641 Evaluation of the impact of systematic delivery of cessation interventions on delivery of smoking cessation in secondary care www.isrctn.com\/ISRCTN25441641"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1940-0640-9-9","article-title":"Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics","volume":"9","author":"Nahvi","year":"2014","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0236|cit236","unstructured":"NCT00554840 Comparison of varenicline and placebo for smoking cessation in schizophrenia ClinicalTrials.gov\/ct2\/show\/NCT00554840"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0237|cit237","unstructured":"NCT00580853 The effect of varenicline (Chantix) and bupropion (Zyban) on smoking lapse behavior ClinicalTrials.gov\/ct2\/"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0238|cit238","unstructured":"NCT00683280 Contingency management and pharmacotherapy for smoking cessation ClinicalTrials.gov\/show\/NCT00683280"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0239|cit239","unstructured":"NCT00786149 Improving varenicline adherence and outcomes in homeless smokers ClinicalTrials.gov\/show\/NCT00786149"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0240|cit240","unstructured":"NCT00879177 Contingency management for initiating smoking abstinence in patients with hypertension ClinicalTrials.gov\/show\/NCT00879177"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0241|cit241","unstructured":"NCT00906386 Methadone maintenance treatment and smoking cessation (MMTASC) ClinicalTrials.gov\/ct2\/"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0242|cit242","unstructured":"NCT00918307 Comparison of the efficacy and safety of varenicline versus placebo for smoking cessation among HIV-infected patients. A randomized double blind controlled trial ClinicalTrials.gov\/show\/NCT00918307"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0243|cit243","unstructured":"NCT00918307 Efficacy and safety of varenicline amongst HIV-infected patients (Inter-ACTIV) ClinicalTrials.gov\/ct2\/"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0244|cit244","unstructured":"NCT00921388 Exercise for smoking cessation in postmenopausal women ClinicalTrials.gov\/show\/NCT00921388"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0245|cit245","unstructured":"NCT00931021 Smoking cessation treatment for head and neck cancer patients ClinicalTrials.gov\/ct2\/"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0246|cit246","unstructured":"NCT00937235 Treatment of smoking among individuals with PTSD: a phase II, randomized study of varenicline and cognitive behavioral therapy ClinicalTrials.gov\/show\/NCT00937235"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0247|cit247","unstructured":"NCT00943618 Combining varenicline and bupropion for smoking cessation ClinicalTrials.gov\/ct2\/"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0248|cit248","unstructured":"NCT01067612 Extended treatment for smoking cessation [NRT, bupropion and varenicline] ClinicalTrials.gov\/ct2\/"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0249|cit249","unstructured":"NCT01093937 Study of varenicline for smoking cessation\/reduction in patients with bipolar disorder ClinicalTrials.gov\/ct2\/"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0250|cit250","unstructured":"NCT01162239 Maintaining nonsmoking ClinicalTrials.gov\/show\/NCT01162239"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0251|cit251","unstructured":"NCT01170338 Safety and efficacy of varenicline in patients with acute coronary syndrome ClinicalTrials.gov\/ct2\/"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0252|cit252","unstructured":"NCT01243203 Smoking cessation program in the preadmission clinic: the use of a teachable moment ClinicalTrials.gov\/show\/NCT01243203"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0253|cit253","unstructured":"NCT01286584 Varenicline in residential treatment (ViRT) ClinicalTrials.gov\/ct2\/"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0254|cit254","unstructured":"NCT01312909 A twelve-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study with follow-up evaluating the safety and efficacy of varenicline for smoking cessation in healthy adolescent smokers ClinicalTrials.gov\/show\/NCT01312909"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0255|cit255","unstructured":"NCT01312909 Smoking cessation study in healthy adolescent smokers ClinicalTrials.gov\/ct2\/"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub7-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1158\/1055-9965.EPI-14-0427","article-title":"Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers","volume":"23","author":"Chenoweth","year":"2014","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0257|cit257","unstructured":"NCT01314001 Pharmacogenetics of nicotine addiction treatment ClinicalTrials.gov\/ct2\/"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0258|cit258","unstructured":"NCT01320462 Smoking cessation program in the preadmission clinic ClinicalTrials.gov\/ct2\/"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0259|cit259","unstructured":"NCT01387425 Efficacy and safety of smoking cessation with varenicline tartrate in diabetic smokers (DIASMOKE) ClinicalTrials.gov\/ct2\/"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0260|cit260","unstructured":"NCT01413516 A Two-Part Pilot Study of Dosing, Safety and Efficacy of Varenicline Initiated During an Acute Smoke-free Hospitalization and Continued Post-Hospitalization Http:\/\/clinicaltrials.gov\/show\/NCT01413516 2011"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0261|cit261","unstructured":"NCT01509547 A randomized controlled trial of varenicline for adolescent smoking cessation ClinicalTrials.gov\/show\/NCT01509547"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0262|cit262","unstructured":"NCT01531049 Smoking cessation in young adults in Northern Finland ClinicalTrials.gov\/show\/NCT01531049"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0263|cit263","unstructured":"NCT01532232 Treatment of tobacco dependence in breast cancer patients: a randomized trial of varenicline (Chantix) ClinicalTrials.gov\/show\/NCT01532232"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0264|cit264","unstructured":"NCT01538394 Clinical trial to evaluate the efficacy of smoking cessation ClinicalTrials.gov\/ct2\/results?term=NCT01538394"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0265|cit265","unstructured":"NCT01553136 1\/2-multi-site study: varenicline treatment of alcohol dependent smokers ClinicalTrials.gov\/show\/NCT01553136"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0266|cit266","unstructured":"NCT01574703 Study to evaluate cardiac assessments following different treatments of smoking cessation medications in subjects with and without psychiatric disorders [CATS] ClinicalTrials.gov\/show\/NCT01574703"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0267|cit267","unstructured":"NCT01592695 Tailored tobacco cessation program for rural veterans with comorbid depression, alcoholism or obesity ClinicalTrials.gov\/show\/NCT01592695"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0268|cit268","unstructured":"NCT01623505 Reducing cardiovascular disease by combining smoking cessation pharmacotherapy and behavioural counselling ClinicalTrials.gov\/ct2\/results?term=NCT01623505"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0269|cit269","unstructured":"NCT01639560 Varenicline for light smokers (ChanLight) ClinicalTrials.gov\/ct2\/show\/NCT01639560?term=NCT01639560&rank=1"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0270|cit270","unstructured":"NCT01694732 Efficacy of varenicline associated with intensive counselling versus placebo of varenicline associated with intensive counselling on smoking cessation at the acute phase of an exacerbation of chronic obstructive pulmonary disease (COPD). A multicenter randomized double-blind trial ClinicalTrials.gov\/show\/NCT01694732"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0271|cit271","unstructured":"NCT01710137\/S A placebo controlled trial of varenicline for smoking among those with HIV\/AIDS ClinicalTrials.gov\/show\/NCT01710137"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0272|cit272","unstructured":"NCT01756885 Extended duration varenicline for smoking among cancer patients: a clinical trial ClinicalTrials.gov\/show\/NCT01756885"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0273|cit273","unstructured":"NCT01771627 Pilot study of varenicline vs. nicotine patch delivered by a telephone quitline to promote smoking cessation ClinicalTrials.gov\/show\/NCT01771627"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0274|cit274","unstructured":"NCT01772641 A combination of scheduled reduced smoking with varenicline to enhance cessation ClinicalTrials.gov\/show\/NCT01772641"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0275|cit275","unstructured":"NCT01800019 The Canadian HIV quit smoking trial: tackling the co-morbidities of depression and cardiovascular disease in HIV+ smokers ClinicalTrials.gov\/show\/NCT01800019"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0276|cit276","unstructured":"NCT01850953 Evaluating the effects of varenicline on smoking lapse in smokers with and without schizophrenia: implications for treatment ClinicalTrials.gov\/show\/NCT01850953"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0277|cit277","unstructured":"NCT01892813 Tailored tobacco intervention ClinicalTrials.gov\/show\/NCT01892813"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0278|cit278","unstructured":"NCT01898195 Improving adherence to smoking cessation medication among PLWHA ClinicalTrials.gov\/show\/NCT01898195"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0279|cit279","unstructured":"NCT02048917 Optimization of smoking cessation strategies in community cancer programs for newly diagnosed lung and head and neck cancer patients Clinicaltrials.gov\/show\/NCT02048917"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0280|cit280","unstructured":"NCT02106637 Early in-hospital initiation of pharmacotherapy for smoking cessation, concomitant with nurse-led support, in patients after an acute coronary syndrome (ACS) ClinicalTrials.gov\/show\/NCT02106637"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0281|cit281","unstructured":"NCT02136498 Internet-based medication adherence program for nicotine dependence treatment ClinicalTrials.gov\/show\/NCT02136498"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0282|cit282","unstructured":"NCT02146911 Evaluating the real-world effectiveness of varenicline and bupropion for long-term smoking cessation ClinicalTrials.gov\/show\/NCT02146911"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0283|cit283","unstructured":"NCT02147132 A pilot randomized, placebo-controlled, crossover study of the effect of the nicotine nasal spray and varenicline on cigarette smoking following methadone dosing in methadone-maintained patients ClinicalTrials.gov\/show\/NCT02147132"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0284|cit284","unstructured":"NCT02162849 The effects of behavioral counseling plus nicotine replacement therapy (NRT) or varenicline on smoking cessation among smokers high and low in intrinsic reward sensitivity ClinicalTrials.gov\/show\/NCT02162849"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0285|cit285","unstructured":"NCT02271919 Varenicline and combined nicotine replacement therapy (NRT) for initial smoking cessation and rescue Treatment in smokers: a randomized pilot trial ClinicalTrials.gov\/show\/NCT02271919"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0286|cit286","unstructured":"NCT02328794 Randomized clinical trial to reduce harm from tobacco ClinicalTrials.gov\/show\/NCT02328794"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0287|cit287","unstructured":"NCT02351167 Genetically informed smoking cessation trial ClinicalTrials.gov\/show\/NCT02351167"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0288|cit288","unstructured":"NCT02360631 Advancing tobacco use treatment for African American smokers ClinicalTrials.gov\/show\/NCT02360631"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0289|cit289","unstructured":"NCT02367391 Pilot randomized trial of an automated smoking cessation intervention via mobile phone text messages as an adjunct to varenicline in primary care ClinicalTrials.gov\/show\/NCT02367391"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0290|cit290","unstructured":"NCT00959972 Varenicline versus transdermal nicotine patch for smoking cessation in patients with coronary heart disease http:\/\/clinicaltrials.gov\/ct2\/"},{"issue":"Supplement D","key":"10.1002\/14651858.CD006103.pub7-BIB0291|cit291","first-page":"53D","article-title":"Varenicline versus transdermal nicotine patch for smoking cessation in patients with coronary heart disease: A pilot randomized trial","volume":"26","author":"Reid","year":"2010","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0292|cit292","unstructured":"NCT00756275 Varenicline and motivational advice for smokers with substance use disorders ClinicalTrials.gov\/ct2\/show\/NCT00756275"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0293|cit293","unstructured":"Rohsenow DJ Tidey JW Martin RA Colby SM Monti PM Varenicline helps smokers with SUD stop smoking without harming recovery (POS5-63) Society for Research on Nicotine and Tobacco 21st Annual Meeting February 25-28 Philadelphia 2015"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0294|cit294","unstructured":"NCT00802919 Varenicline for cognitive deficits and cigarette smoking in schizophrenia ClinicalTrials.gov\/ct2\/show\/NCT00802919"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0295|cit295","first-page":"S364","article-title":"Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia","volume":"38","author":"Smith","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cct.2014.05.011","article-title":"Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose nicotine replacement therapy for smoking cessation: rationale, methods and participant characteristics of the FLEX trial","volume":"38","author":"Tulloch","year":"2014","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0297|cit297","unstructured":"EUCTR2009-016446-50\/NL Helping more smokers to quit by combining varenicline with counselling for smoking cessation. The COVACO randomized controlled trial ClinicalTrialsregister.eu\/ctr-search\/trial\/2009-016446-50\/NL"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.cct.2015.01.017","article-title":"Combining intensive practice nurse counselling or brief general practitioner advice with varenicline for smoking cessation in primary care: Study protocol of a pragmatic randomized controlled trial","volume":"41","author":"Rossem","year":"2015","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0299|cit299","unstructured":"Raw M McNeill A Arnott D Varenicline: guidance for health professionals on a new prescription-only stop smoking medication www.ash.org.uk\/html\/cessation\/ASHVareniclineguidance.pdf (accessed November 2006) 2006"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0095-4543(05)70120-2","article-title":"Nicotine addiction","volume":"26","author":"Benowitz","year":"1999","journal-title":"Primary Care"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0301|cit301","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009329.pub2","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis","author":"Cahill","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0302|cit302","unstructured":"Carston K Personal communication December 2011"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1021\/jm050069n","article-title":"Varenicline: an alpha4beta2 nAChR nicotinic receptor partial agonist for smoking cessation","volume":"48","author":"Coe","year":"2005","journal-title":"Journal of Medicinal Chemistry"},{"issue":"12","key":"10.1002\/14651858.CD006103.pub7-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/S2213-2600(15)00468-3","article-title":"Cardiovascular and neuropsychiatric risks of varenicline: too good to be true?","volume":"3","author":"Davies","year":"2015","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0305|cit305","unstructured":"Drovandi AD Chen CC Glass BD Adverse effects cause varenicline discontinuation: a meta-analysis Current Drug Safety"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0306|cit306","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004306.pub4","article-title":"Interventions for smokeless tobacco use cessation","author":"Ebbert","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archinte.166.15.1553","article-title":"Cytisine for smoking cessation: a literature review and a meta-analysis","volume":"166","author":"Etter","year":"2006","journal-title":"Archives of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1360-0443.2007.01822.x","article-title":"The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis","volume":"102","author":"Etter","year":"2007","journal-title":"Addiction"},{"issue":"1-3","key":"10.1002\/14651858.CD006103.pub7-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.drugalcdep.2007.06.017","article-title":"Cytisine for smoking cessation: a research agenda","volume":"92","author":"Etter","year":"2008","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1517\/13543784.15.2.107","article-title":"Neuropharmacology and potential efficacy of new treatments for tobacco dependence","volume":"15","author":"Fagerstr\u00f6m","year":"2006","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0311|cit311","unstructured":"US Food Drug Administration FDA issues Public Health Advisory on Chantix www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2008\/ucm116849.htm"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0312|cit312","unstructured":"U. S. Food Drug Administration FDA drug safety communication: safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm276737.htm (accessed 19\/1\/2012) October 2011"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0313|cit313","unstructured":"U.S. Food Drug Administration FDA drug safety communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm259161.htm (accessed 19\/1\/2012) June 2011"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0314|cit314","unstructured":"U.S. Food Drug Administration Adverse Events Reporting System (AERS) http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm (accessed 5\/1\/2012) 2012"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0315|cit315","unstructured":"U. S. Food Drug Administration FDA updates label for stop smoking deug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures and studies of side effects on mood, behavior, or thinking www.fda.gov\/Drugs\/DrugSafety\/ucm436494.htm"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/14728214.9.1.39","article-title":"Advances in pharmacotherapy for tobacco dependence","volume":"9","author":"Foulds","year":"2004","journal-title":"Expert Opinion on Emerging Drugs"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/11589350-000000000-00000","article-title":"Strategies for quantifying the relationship between medications and suicidal behaviour","volume":"34","author":"Gibbons","year":"2011","journal-title":"Drug Safety"},{"issue":"12","key":"10.1002\/14651858.CD006103.pub7-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1176\/appi.ajp.2013.12121599","article-title":"Varenicline, smoking cessation and neuropsychiatric adverse events","volume":"170","author":"Gibbons","year":"2013","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"b3805","DOI":"10.1136\/bmj.b3805","article-title":"Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database","volume":"339","author":"Gunnell","year":"2009","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub7-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2165\/11594450-000000000-00000","article-title":"Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand","volume":"34","author":"Harrison-Woolrych","year":"2011","journal-title":"Drug Safety"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/11597690-000000000-00000","article-title":"Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand","volume":"35","author":"Harrison-Woolrych","year":"2012","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/ije\/dyg203","article-title":"Smoking at age 18-20 and suicide during 26 years of follow-up - how can the association be explained?","volume":"32","author":"Hemmingsson","year":"2003","journal-title":"international Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"7414","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0324|cit324","unstructured":"Higgins JPT Green S (eds) Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011] http:\/\/www.cochrane-handbook.org 2011"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bcp.2006.08.010","article-title":"Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors","volume":"73","author":"Hogg","year":"2007","journal-title":"Biochemical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/1462220031000070552","article-title":"Measures of abstinence in clinical trials: issues and recommendations","volume":"5","author":"Hughes","year":"2003","journal-title":"Nicotine & Tobacco Research"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0327|cit327","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000031.pub4","article-title":"Antidepressants for smoking cessation","author":"Hughes","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0328|cit328","unstructured":"Institute for Safe Medication Practice Quartewatch: 2010 Quarter 3 http:\/\/www.ismp.org\/quarterwatch\/pdfs\/2010Q3.pdf (accessed 19\/1\/2012) 2011"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2165\/00002018-200932060-00006","article-title":"Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study","volume":"32","author":"Kasliwal","year":"2009","journal-title":"Drug Safety"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub7-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1517\/13543780903184591","article-title":"Discontinued psychiatric drugs in 2008","volume":"18","author":"Kirchhoff","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"15","key":"10.1002\/14651858.CD006103.pub7-BIB0331|cit331","first-page":"320","article-title":"Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study","volume":"S2213-2600","author":"Kotz","year":"2015 [Epub ahead of print]","journal-title":"Lancet"},{"issue":"33","key":"10.1002\/14651858.CD006103.pub7-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18330","article-title":"What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? a systematic review and economic evaluation","volume":"18","author":"Leaviss","year":"2014","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1472-6904-11-15","article-title":"Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis","volume":"11","author":"Leung","year":"2011","journal-title":"BMC Clinical Pharmacology"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0334|cit334","unstructured":"McKee SA Smith PH Kaufman M Mazure CM Weinberger AH Sex differences in varenicline efficacy for smoking cessation: a meta-analysis Nicotine & Tobacco Research"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1360-0443.2012.04024.x","article-title":"Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System","volume":"108","author":"Meyer","year":"2013","journal-title":"Addiction (Abingdon, England)"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a partial agonist at a4\u00df2 and a full agonist at a7 neuronal nicotinic receptors","volume":"70","author":"Mihalak","year":"2006","journal-title":"Molecular Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"768","DOI":"10.2105\/AJPH.90.5.768","article-title":"Cigarettes and suicide: a prospective study of 50000 men","volume":"90","author":"Miller","year":"2000","journal-title":"American Journal of Public Health"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub7-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3109\/07853890.2012.705016","article-title":"Comparisons of high-dose and combination nicotine replacement therapy, varenicline and bupropion for smoking cessation: a systematic review and multiple-treatment meta-analysis","volume":"44","author":"Mills","year":"2012","journal-title":"Annals of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.113.003961","article-title":"Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis","volume":"129","author":"Mills","year":"2014","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"h2388","DOI":"10.1136\/bmj.h2388","article-title":"Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study","volume":"351","author":"Molero","year":"2015","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub7-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"e27016","DOI":"10.1371\/journal.pone.0027016","article-title":"Suicidal behaviour and depression in smoking cessation treatments","volume":"6","author":"Moore","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0342|cit342","unstructured":"National Institute for Health and Clinical Excellence Varenicline for smoking cessation http:\/\/www.nice.org.uk\/nicemedia\/pdf\/TA123Guidance.pdf (accessed 14th April 2008) 2007"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0026-895X(25)09896-7","article-title":"Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta2 subunit","volume":"45","author":"Papke","year":"1994","journal-title":"Molecular Pharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006103.pub7-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1080\/14622299050011931","article-title":"Use of knockout mice to determine the molecular basis for the actions of nicotine","volume":"1","author":"Picciotto","year":"1999","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"e2856","DOI":"10.1136\/bmj.e2856","article-title":"Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis","volume":"344","author":"Prochaska","year":"2012","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0346|cit346","unstructured":"Sands SB Brooks PR Chambers LK Coe JW Liu Y Rollema H A new therapy for smoking cessation: varenicline, a selective nicotinic receptor partial agonist [SYM10C] Society for Research on Nicotine and Tobacco 11th Annual Meeting. 20-23 March 2005; Prague, Czech Republic 2005 14"},{"issue":"12","key":"10.1002\/14651858.CD006103.pub7-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1503\/cmaj.110218","article-title":"Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis","volume":"183","author":"Singh","year":"2011","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0028-3908(03)00025-X","article-title":"Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes","volume":"44","author":"Slater","year":"2003","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0349|cit349","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000124","article-title":"Lobeline for smoking cessation","author":"Stead","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub7-BIB0350|cit350","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000146.pub4","article-title":"Nicotine replacement therapy for smoking cessation","author":"Stead","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"e002849","DOI":"10.1161\/JAHA.115.002849","article-title":"Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials","volume":"5","author":"Sterling","year":"2016","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0352|cit352","unstructured":"US Surgeon General The health consequences of smoking: a report of the Surgeon General www.cdc.gov\/tobacco\/sgr\/sgr_2004\/index.htm (accessed 25\/1\/2006) 2004"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"e7176","DOI":"10.1136\/bmj.e7176","article-title":"Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study","volume":"345","author":"Svanstr\u00f6m","year":"2012","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0354|cit354","unstructured":"Sopharma AD http:\/\/www.tabex.net\/41814_packageinsert.phtml (accessed 2\/11\/2011) 2011"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"f5704","DOI":"10.1136\/bmj.f5704","article-title":"Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study","volume":"347","author":"Thomas","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/2050-6511-15-54","article-title":"Reporting of drug induce depression and non-fatal suicidal behaviour in the UK from 1998 to 2011","volume":"15","author":"Thomas","year":"2014","journal-title":"BMC Pharmacology & Toxicology"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"h1109","DOI":"10.1136\/bmj.h1109","article-title":"Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis","volume":"350","author":"Thomas","year":"2015","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub7-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ntr\/ntr002","article-title":"Cytisine's potential to be used as a traditional healing method to help indigenous people stop smoking: a qualitative study with M\u0101ori","volume":"13","author":"Thompson-Evans","year":"2011","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0359|cit359","first-page":"681","article-title":"Varenicline: smoking cessation in patients with medical and psychiatric comorbidity","volume":"2","author":"Tonstad","year":"2010","journal-title":"Clinical Medicine Insights: Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/11319180-000000000-00000","article-title":"Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis","volume":"33","author":"Tonstad","year":"2010","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0361|cit361","first-page":"777","article-title":"Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy","volume":"58","author":"Tutka","year":"2005","journal-title":"Pharmacological Reports"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0362|cit362","first-page":"33","article-title":"Cytisine - renaissance of well known alkaloid. Pharmacological aspects of efficacy in the treatment of tobacco dependence [Polish]","volume":"1","author":"Tutka","year":"2006","journal-title":"Farmakoterapia w Psychiatrii i Neurologii"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub7-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1517\/13543784.17.10.1473","article-title":"Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation","volume":"17","author":"Tutka","year":"2008","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0364|cit364","unstructured":"VA Center for Medication Safety Varenicline criteria for prescribing http:\/\/www.pbm.va.gov\/Clinical%20Guidance\/Criteria%20For%20Use\/Varenicline%20Criteria%20for%20Prescribing.doc (accessed 19\/1\/2012) 2011"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1360-0443.2010.03282.x","article-title":"Australia's experience with varenicline: usage, costs and adverse reactions [letter]","volume":"106","author":"Walsh","year":"2011","journal-title":"Addiction"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MJT.0b013e31828d455b","article-title":"Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials","volume":"20","author":"Ware","year":"2013","journal-title":"American Journal of Therapeutics"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1360-0443.2004.00995.x","article-title":"Outcome criteria in smoking cessation trials: proposal for a common standard","volume":"100","author":"West","year":"2005","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006103.pub7-BIB0368|cit368","unstructured":"World Health Organization WHO Global Report: Mortality Attributable to Tobacco apps.who.int\/iris\/bitstream\/10665\/44815\/1\/9789241564434_eng.pdf"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub7-BIB0369|cit369","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub2","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Cahill","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0370|cit370","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub3","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Cahill","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub7-BIB0371|cit371","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub5","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Cahill","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub7-BIB0372|cit372","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub6","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Cahill","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub7-BIB0373|cit373","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Hey","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006103.pub8","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006103.pub7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T22:14:36Z","timestamp":1748902476000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006103.pub7"}},"subtitle":[],"editor":[{"name":"Cochrane Tobacco Addiction Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,9]]},"references-count":373,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006103.pub7","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,9]]}}}